Three things to know:
1. Carmell Therapeutics develops plasma-based bioactive materials to accelerate bone and soft tissue healing.
2. In a Phase II clinical trial for open tibia fractures, the company’s bone healing accelerant showed a significant reduction of infections compared to controls, with a clear path toward accelerated wound healing at 30 days.
3. The product can be administered in several forms, including putties, pastes and surgical screws.
More articles on biologics:
AAOS publishes clinical considerations for return to elective surgery
97% of medical practices suffer COVID-19 financial hit: 5 observations for orthopedics
Investor pays $49M for Arizona spine, orthopedic hospital property
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
